HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AHA comments

This article was originally published in The Rose Sheet

Executive Summary

Use of lactic acid or citric acid in concentrations below .3% in cosmetics should be exempted from FDA's alpha hydroxy acid labeling guidance, Win Chiou, PhD, University of Illinois, says in March 25 comments to the agency. Two compounds are expected to be safe at low concentrations and often are used as electrolytes, nutrients or buffering agents, Chiou adds. Comments echo those submitted by the Cosmetic, Toiletry and Fragrance Association in January (1"The Rose Sheet" Feb. 10, 2003, p. 3)...

You may also be interested in...



AHA Labeling Exemptions, Minimum Threshold Urged By CTFA

Alpha hydroxy acid "sunburn alert" labeling requirements should not apply to certain products depending on their use or if they fall below a specific AHA concentration threshold, the Cosmetic, Toiletry and Fragrance Association maintains in Jan. 31 comments to FDA

EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions

It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.

How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies

UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel